[Radioimmunoassay of beta sub unit HCG following hydatidiform mole or chorionic carcinoma (author's transl)].
The radioimmunoassay of Beta Sub Unit HCG in the serum heralds a marked improvement in the diagnosis of gestational trophoblastic disease. In nine cases of hydatidiform mole and three cases of chorionic carcinoma serial examinations of the Beta Sub Unit HCG were performed. When the immunologic pregnancy test became negative following a hydatidiform mole or following treatment of chorionic carcinoma, the HCG excretion remained above detectable values for several more weeks. The decrease of Beta Sub Unit serum HCG was either linear or in fluctuations. The detection of fluctuations or a secondary rise in the Beta Sub Unit HCG titre permits the early diagnosis of invasive trophoblastic disease following hydatidiform mole or of insufficient treatment or recurrence in cases of chorionic carcinoma. Our results suggest that the optimal follow-up with Beta Sub Unit serum HCG is by weekly determinations until four consecutive determinations remained negative. This is followed by two determinations at bi-weekly intervals and thereafter monthly follow-up examinations.
D000328:Adult; D002822:Choriocarcinoma / Q000097:blood*; D006063:Chorionic Gonadotropin / Q000097:blood*; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000097:blood*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D011247:Pregnancy; D014594:Uterine Neoplasms / Q000097:blood*
D006063:Chorionic Gonadotropin
Bestimmung von HCG beta nach blasenmole und Chorionepitheliom.